S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
UK travelers face hours-long waits for ferries to France
Credit Suisse takeover hits heart of Swiss banking, identity
Urgent Warning (Ad)
Small areas reopen near Fukushima nuclear plant, few return
'War of the states': EV, chip makers lavished with subsidies
Urgent Warning (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
UK travelers face hours-long waits for ferries to France
Credit Suisse takeover hits heart of Swiss banking, identity
Urgent Warning (Ad)
Small areas reopen near Fukushima nuclear plant, few return
'War of the states': EV, chip makers lavished with subsidies
Urgent Warning (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
UK travelers face hours-long waits for ferries to France
Credit Suisse takeover hits heart of Swiss banking, identity
Urgent Warning (Ad)
Small areas reopen near Fukushima nuclear plant, few return
'War of the states': EV, chip makers lavished with subsidies
Urgent Warning (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
UK travelers face hours-long waits for ferries to France
Credit Suisse takeover hits heart of Swiss banking, identity
Urgent Warning (Ad)
Small areas reopen near Fukushima nuclear plant, few return
'War of the states': EV, chip makers lavished with subsidies
Urgent Warning (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
NASDAQ:TENX

Tenax Therapeutics - TENX Stock Forecast, Price & News

$0.46
-0.03 (-6.06%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.46
▼
$0.49
50-Day Range
$0.46
▼
$2.57
52-Week Range
$0.45
▼
$17.00
Volume
1.76 million shs
Average Volume
9.47 million shs
Market Capitalization
$1.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Tenax Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,190.3% Upside
$6.00 Price Target
Short Interest
Bearish
24.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.33mentions of Tenax Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($9.31) to ($0.97) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

See Top Rated MarketRank™ Stocks Here

TENX stock logo

About Tenax Therapeutics (NASDAQ:TENX) Stock

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Receive TENX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TENX Stock News Headlines

March 31, 2023 | seekingalpha.com
TENX Tenax Therapeutics, Inc.
March 25, 2023 | americanbankingnews.com
Tenax Therapeutics (NASDAQ:TENX) Upgraded by StockNews.com to Sell
April 2, 2023 | Legacy Research (Affiliate) (Ad)
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
March 22, 2023 | finance.yahoo.com
Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
March 8, 2023 | msn.com
Roth MKM Initiates Coverage of Tenax Therapeutics (TENX) with Buy Recommendation
March 7, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT), Tenax Therapeutics (TENX) and Day One Biopharmaceuticals (DAWN)
February 17, 2023 | finance.yahoo.com
Analysts Are Optimistic We'll See A Profit From Tenax Therapeutics, Inc. (NASDAQ:TENX)
February 15, 2023 | finance.yahoo.com
TENX: New Funding Puts Wind in the Sails
April 2, 2023 | Legacy Research (Affiliate) (Ad)
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
February 7, 2023 | finance.yahoo.com
Triangle pharma raising millions amid uncertain future
February 3, 2023 | marketwatch.com
Tenax Therapeutics Down 20% After Offering Gets Priced
February 3, 2023 | msn.com
Tenax Therapeutics stock dips after pricing $15.6M securities offering
February 3, 2023 | finance.yahoo.com
Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering
February 2, 2023 | marketwatch.com
Tenax Therapeutics Shares Rise 73%, Co. Gets Patent for Hypertension Treatment
February 2, 2023 | finance.yahoo.com
Why Tenax Therapeutics Shares Are Gaining Today?
February 2, 2023 | investorplace.com
Why Is Tenax Therapeutics (TENX) Stock Up 149% Today?
February 1, 2023 | marketwatch.com
Tenax Shares Double After Hours, Co. Gets Patent for Use of IV Levosimendan in PH-HFpEF
February 1, 2023 | tmcnet.com
Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension
February 1, 2023 | finance.yahoo.com
Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
January 25, 2023 | reuters.com
TENX.OQ - | Stock Price & Latest News | Reuters
January 25, 2023 | marketwatch.com
Tenax Therapeutics Shares Decline 18% On Plans to Offer Stocks, Warrants
January 9, 2023 | bizjournals.com
Morrisville firm takes action to avoid Nasdaq delisting amid potential sale
January 4, 2023 | finance.yahoo.com
Tenax Therapeutics Announces Reverse Stock Split
November 3, 2022 | finance.yahoo.com
TENX: Agility Required to Unlock Considerable Upside
October 10, 2022 | finance.yahoo.com
Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
October 4, 2022 | msn.com
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
September 16, 2022 | marketwatch.com
Tenax Therapeutics to Explore Options, Including Sale >TENX
See More Headlines
Receive TENX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TENX Company Calendar

Last Earnings
11/16/2021
Today
4/01/2023
Next Earnings (Estimated)
5/15/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TENX
CUSIP
N/A
CIK
34956
Web
www.tenaxthera.com
Phone
919-855-2100
Fax
919-855-2133
Employees
8
Year Founded
1967

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+1,190.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-32,470,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-282.26%
Return on Assets
-205.15%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.54
Quick Ratio
6.54

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.37 per share
Price / Book
0.14

Miscellaneous

Outstanding Shares
2,310,000
Free Float
1,061,000
Market Cap
$1.07 million
Optionable
Not Optionable
Beta
2.15

Social Links


Key Executives

  • Mr. Christopher T. Giordano (Age 48)
    CEO, Pres & Director
    Comp: $279.44k
  • Mr. Eliot M. Lurier CPA (Age 65)
    Interim Chief Financial Officer
    Comp: $25.9k
  • Dr. Stuart Rich M.D. (Age 73)
    Chairman of Scientific Advisory Board, Chief Medical Officer & Director
    Comp: $415.53k
  • Ms. Nancy J. M. Hecox
    Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.
  • Mr. Doug Randall
    Exec. VP of Commercial & Bus. Operations
  • Dr. Douglas Hay
    Sr. VP of Regulatory Affairs

Key Competitors

View All Competitors













TENX Stock - Frequently Asked Questions

Should I buy or sell Tenax Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tenax Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TENX shares.
View TENX analyst ratings or view top-rated stocks.

What is Tenax Therapeutics' stock price forecast for 2023?

2 Wall Street analysts have issued 1 year price targets for Tenax Therapeutics' stock. Their TENX share price forecasts range from $6.00 to $6.00. On average, they predict the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,190.3% from the stock's current price.
View analysts price targets for TENX or view top-rated stocks among Wall Street analysts.

How have TENX shares performed in 2023?

Tenax Therapeutics' stock was trading at $0.1114 at the beginning of 2023. Since then, TENX stock has increased by 317.4% and is now trading at $0.4650.
View the best growth stocks for 2023 here.

Are investors shorting Tenax Therapeutics?

Tenax Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 2,160,000 shares, an increase of 387.7% from the February 28th total of 442,900 shares. Based on an average daily volume of 3,860,000 shares, the short-interest ratio is presently 0.6 days. Currently, 24.8% of the shares of the company are sold short.
View Tenax Therapeutics' Short Interest.

When is Tenax Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our TENX earnings forecast.

How were Tenax Therapeutics' earnings last quarter?

Tenax Therapeutics, Inc. (NASDAQ:TENX) posted its quarterly earnings results on Tuesday, November, 16th. The specialty pharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.02.

When did Tenax Therapeutics' stock split?

Shares of Tenax Therapeutics reverse split before market open on Monday, February 26th 2018. The 1-20 reverse split was announced on Friday, February 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Tenax Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tenax Therapeutics investors own include Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Idera Pharmaceuticals (IDRA), NVIDIA (NVDA), SCYNEXIS (SCYX), Verastem (VSTM), Bank of Hawaii (BOH), Gilead Sciences (GILD) and AVEO Pharmaceuticals (AVEO).

What is Tenax Therapeutics' stock symbol?

Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX."

How do I buy shares of Tenax Therapeutics?

Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tenax Therapeutics' stock price today?

One share of TENX stock can currently be purchased for approximately $0.47.

How much money does Tenax Therapeutics make?

Tenax Therapeutics (NASDAQ:TENX) has a market capitalization of $1.07 million.

How can I contact Tenax Therapeutics?

Tenax Therapeutics' mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The official website for the company is www.tenaxthera.com. The specialty pharmaceutical company can be reached via phone at 919-855-2100, via email at jesse@sternir.com, or via fax at 919-855-2133.

This page (NASDAQ:TENX) was last updated on 4/2/2023 by MarketBeat.com Staff